ArticlePharmacoEconomics2011

Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Helen Dakin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.